Intricacies for posttranslational tumor-targeted cytokine gene therapy

Area of Science:

• Oncology
• Gene Therapy
• Immunotherapy

Background:

• Effective cytokine therapies necessitate localized accumulation within the tumor microenvironment.
• Systemic tumor-targeted delivery offers a more feasible approach than direct intratumoral injection.
• Electroporation-mediated plasmid DNA transfection enables endogenous production of tumor-targeted cytokines.

Purpose of the Study:

• To investigate how targeting peptide location and choice influence the efficacy of cytokine gene therapy.
• To evaluate the impact of different tumor histotypes and cytokines on treatment outcomes.
• To assess the feasibility and personalization of systemic tumor-targeted cytokine gene therapies.

Main Methods:

• Utilized multiple syngeneic murine tumor models.
• Employed electroporation-mediated transfection of cytokine plasmid DNA encoding tumor-targeting peptides.
• Varied the location and type of targeting peptides, as well as the specific cytokines (IL12, IL15, PF4).

Main Results:

• The location of the targeting peptide significantly impacted the antitumor effect of interleukin (IL)12 gene treatments in a tumor-model-dependent manner.
• In some models, tumor-targeted IL12 plasmid DNA efficacy was independent of peptide location.
• A targeting peptide that enhanced IL12 therapy in one model did not improve IL15 or PF4 efficacy in the same model.

Conclusions:

• Tumor-targeted cytokine gene therapies demonstrate both efficacy and the need for personalization.
• Careful consideration of targeting peptide characteristics and tumor type is essential for clinical translation.
• Further research is required to optimize these therapies for approved treatment options.